|
|
 |
|
Viewing report
|
|
|
|
The Complete Guide to Targeted Therapies in Oncology: A World Review
Bioseeker, Dec 2006, Pages: 550
Introduction
The dogma for treatment of cancer has changed, with the cytotoxic drugs used in chemotherapy regimes set to lose their dominance and be used alongside targeted therapies that are being developed with the aim of more specifically targeting cancer cells.
Research and analysis highlights
In this comprehensive report covering targeted therapies in oncology, BioSeeker Group has analyzed apoptopic agents, protein kinase inhibitors, anti-angiogenic and vascular targeting agents, immunostimulators, antibodies and vaccines in oncology.
This extensive 550+ pages report compiles and analyzes in parallel the progress concerning drug development and competitive situation in the mentioned key oncology targeted therapy areas. The report will not only provide a framework but also a careful identification and evaluation of drug candidates, technologies and competitors.
The number of targeted therapy drugs has risen sharply, as have the number of targets. The fiercest competition in oncology targeted therapy is pointed out and how several big pharma companies are out hunting for promising technology and drugs to complement their internal pipeline.
Scope of this report
- In-depth competitive landscape assessment of the targeted oncology market place; Including more than 340 drugs and pharmaceutical companies
- Thorough review of six major targeting strategies in oncology: Apoptosis agents, Protein kinase inhibitors, Anti-angiogenic and vascular targeting agents, Immunostimulators, Antibodies and Vaccines
- Progress analysis of major cancer indications for respective targeting strategy, including players, drugs, clinical progress and pitfalls
- Includes more than 120 Tables, 60 Boxes and close to 40 Figures
Key reasons to read this report
- Understand the clinical and strategic challenges to the commercialization of aix major targeting strategies in oncology
- Assess opportunities and risks for the continued development of targeting agents in major cancer indications.
- Adopt knowledge from this analysis to drive strategic planning decisions in oncology drug development
Customers who bought this item also bought
Triple Analysis: The Drug Target Atlas of Apoptopic Drugs in Oncology and Special Focus on Breast and Prostate Cancer
Triple Analysis: The Drug Target Atlas of Apoptopic Drugs in Oncology and Special Focus on Lung Cancer and Melanoma
Antibody Drug Targets and Focus on Breast & Prostate Cancer
Triple Analysis: Non Small Cell Lung Cancer, Protein Kinase Inhibitors & Anti-Angiogenic Agents
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Breast- and Prostate Cancer
Triple Analysis: Apoptosis Agents, Protein Kinase Inhibitors and Anti-Angiogenic Agents in Oncology
Cancer Drug Resistance
Drug Delivery in Cancer - Technologies, Markets and Companies
Triple Analysis: Decoding Big Pharma's R&D Strategy In Oncology and Special Focus on Breast and Prostate Cancer
The Drug Target Atlas of Protein Kinase Inhibitors in Oncology
Competitive Insights to Anti-Angiogenic Drug R&D in Oncology
Prostate and Breast Cancer- New Treatments & Developmental Progress
|
|
|
|
